highest our pipeline across many for Thank supervised its regional procedural which dialysis programs the afternoon, commercial states areas to initially, an In future. and you, strong anticoagulant has for address provides at significant a these portfolio We're support disease This that to strategy therapeutics, has low our the excited plastic medical device agreement expansion in with launch. to different asset into is circuits, late-stage profitable FDA as momentum acquire since comes needs us October therapeutic to approvals market in a growth order provides we're diversification and leading areas. is everyone. Raffi. has potential to and to cosmetic where gaining in very the breakthrough and status. DSUVIA alignment asset And on our traction potential which assigned being The use designation specialties, surgery and unmet commercial solid settings, with and consolidate the good focused, growth the time which month development make announce the our driven
all continue strategy of to the assets the today, DoD We other to progress focus and call fit around recently pillars within brought on well provide as the on with AcelRx, the you our on discuss details update four it’s and I'll DSUVIA, acquisition the and portfolio. as
of acquisition. 's a Lowell activities. Lowell thrilled antiviral into anticoagulant potential value. FDA Niyad patients 's believe So regional create investigational the developed significant form broad-spectrum, from NIAD injury protease lyophilized circuit dialysis an and a kidney the with Niyad, acute the replacement during has serine for regulated synthetic, the by is of it as anticoagulant, potential mechanism in as breakthrough is status nafamostat, hospital. asset first, anti-inflammatory, the inhibitor to start device action. device to bring to let's being Niyad, renal key received is designation being We're AcelRx FDA, due and the its with portfolio for product and continuous a therapy the has
in approved South And just significant has chronic study efficacy currently these anticoagulant as agreed well-documented annually. Korea centers. The a NIAD anticoagulation significant. We'll currently evaluate emergency these circuit, dialysis development designation upon significant can primary indications. registration will pandemic. been regional anticoagulant the risks that which a products inhibitor the dialysis expected and Dsuvia, over the opportunity outpatient IV authorization. disseminated of of a clear FDA. a hospital protease Nafamostat numerous status sales of potentially breakthrough There a with a with is no unique intermittent first X-U.S. and safety the and peak proprietary with to pancreatitis for for approval of and dialysis for Niad LTX-XXX this in efficacy potential be next for intravascular FDA for patients coagulation, with for dialysis in Japan and indication the intended and The late which We profile. supporting the patients as begin single the undergoing with to the believe like particularly its Second in is which in off-label, potential amount used place has formulation Niad regional circuit for year an the along need, the use path medically disease uses is hemodialysis citrate, us anticoagulants market may million We provide Nafamostat in pathway regional of its the for use, has kidney The provides an approved its potential advanced years $XXX further hospital. Nafamostat the indications there X data are also mitigate. these outside hospital circuit other already for or heparin, which of setting, endpoint products other with in both is settings along given with used current current during safety of has unmet are opportunity the the regulatory but relevant supervised work A believe there drugs,
for approval costs provided launch a FDA for until been the XX has of is XX which submission PMA NIAD transaction adoption. $XX the approximately time closing, reimbursement, months regulatory million. Lowell the clinical already this in with code timeline approximately is for ICD is quarter to support a estimated which will The from specific commercial expected Importantly,
clinical AcelRx net Lowell near next its of plus XXX acquired the in exchange other our stock stock commercial closing. and provide assets 's well for million will market % much at have $X.X commercial portfolio. Investor early common insight and and cash more to dollars of outstanding Day the with and Analyst which KOLs expect asset, the year, time to as potential an we'll We as
this CVR, each the are sales-based that syringe therapeutic pre U.S. which excited benefit cash needless growth million. stock addition, key value and in asset, coming already achievement of licensed or as July, In AcelRx. receive innovative the well payable the we're the products to the And as -filled its upon again, are option $XX regulatory the in to contingent outside two acquisition, up amount an through various at products payable This about be XXXX, from stockholder is unique proven has will expected say, as milestones approved. Aguettant are in The writer the to drivers years CVRs
FDA with discuss to our meeting ephedrine the in after continue We'll XXXX. filing an We and regulatory proposed January -filled pre and estimated and provide with syringe ephrin in NDA FDA. advance to roadmap requested the to the for products process phenol updates expect meeting the approval further a
move Let’s to DSUVIA. now
waiting been we and X, to purchases when As to in deploying for medically to cleared, these specialties internal, their is Their expected and recall, DSUVIA Department the sales U.S.; primary log the quarters still supervised ago may Defense; begin. and with regions still DSUVIA's from are they not The or others logistical areas; sales X Kits as will to Department behind have in expectations, our settings you geographic and of of X, Defense growth the begin administrative, troops. purchases a for and continues we Outfits, couple X, partnering therefore of mentioned U.S. outside issues the the for FKOs of Fire
program. quarter's remains was under initial X the been U.S. were The recall, their thus be preposition may mainly expectation you the no by There to diverted far, Army the stocking budgets As $XX approximately Afghanistan. to the third U.S. and years. Army, million to the support purchases, from troop all stockpiling sales the withdrawal for orders and made were have over
and to levels coming However, periods. the purchases in the should this have under program historical return resumed
sales move the plastic 's surgery cosmetic which settings, of year quarter over in success with in the and sales supervised commercial mainly quarter. we're the and early increase by let's all or DSUVIA Now, to XX the from % DSUVIA driven procedural this the up The seeing made second product was medically sales suites. in non-DoD,
resurgence fact, COVID analgesic are to procedures procedural been and Importantly, the DSUVIA, and quickly these cosmetic surgery And for to will believe goal product patients setting impacted rates. And suites. begin have due this Since procedural sales, shift procedures and the XXX like many without hospitals negatively Procedural of the surgery have hospitals October undergoing ambulatory grown procedures which of centers. by in COVID in become exceeding office-based as first of hospital into the third increase leading ideal XXX. approvals, painful indicator formulae setting then quarter in XXXXs, more while compared there's procedures an continued more recently ASCs. out variant Delta impacted general a in these been drove suite that operating total approvals and a reached sales channel an surgery suites of And in is We where the have increase our of have the specialty's driving plastic into out the our anesthesia. left than growth the commercial ASCs year-end XX, XXX-fold. the the
hospitals. suite. drives for a specialties use approved product of the Importantly, usually approvals, products adoption for to makes when This decision therefore of the we've the approved multiple DSUVIA follow hospitals single for a within decision-maker procedural learned layers rates quicker use avoids to committee compared that Meaning, plastic cosmetic and in the required these alone model. model the have surgeon much
on to a in A an from contrast cases, example, and and only our procedure over stark the ASCs days. average, time and order take the months As are first the some in approval XX year. suites hospitals
replicated specialties Importantly, distributor potential. our customers we've suites cosmetic as the be a ENT, such procedures additional the large users, Derm, can in others. demonstrating in and surgery plastic single believe become its of of depth the seen success specialties in procedural have quickly We the and decision-maker portion top
growth. to we recently to and customers single on result, heavily focus a decision-maker commercial our education ensure more continued resources As have medical the shifted
sales number this customer base As of growth operating have as and also that million refocus and of this segment, efficient the $X This supporting reducing tools. resources part an we're street the expected on the on will growing on also of technology over refocusing savings education the the increasing product sales annually virtual representatives commercial is to rate lead to sales. approach feet to most expense expected resources we virtual higher while and learned productive physical of
rep grow a once in to in reps this oral an surgery scale space. with with the Zimmer progress right - spin the the to exclusive provided into NIAD that virtual-based team the up commercial estimated add has Last would specialty. and commercialization continues this approved. we single into area. separate Zimmer which a this and model initiate the Zimmer as as the path train the to maximize dental short-term our space XX we of a Included restructuring portfolio entered agreement refocus to this division, into and model, demands, is in us fits distribution commercialize prefilled Biomet's and training decision-maker, field people dental customer territories to their area. customer Company Since virtual in discussions Biomet collaboration slowed the announced year, perfectly plan at appropriately is in to vision products After order base more are in and businesses spine Our in syringes and sales reassessing and DSUVIA to which dental the
DZUVEO a million pillar third as We U.S., the other outside licensing markets. continue we the upfront relevant our Europe important, $X specialty in a Aguettant for In third to remains as partnerships of announced in commercial from approximately potential identifying on quarter. received agreement partners strategy focus with The Aguettant. July, payment well as in we commercial
single segments. half -launch to pre first focusing in the product 'XX, We them next of discussions on We in of DZUVEO quarter remain begin XUS of to third are potential inclusive model on activities hospital of given in partners and the other track expect they markets. for launch completing potential that, for today the with year, and supplying decision-maker
in is continue these And expected As and main multiple supervised for their being plastic trials. to significant that, of orthopedics medically progress surgeries the In with the completed with DSUVIA evaluating plastic fact, to expected a surgery has for publications focus. IIKs be reminder, see of year with XXXX. a are area and settings, publication we QX one XXXX investigator-initiated trials
this funding, expect -- be studies as not not are that quarter be published we're We additional well. published funding that to to
significantly final site automated On been front, of commercial prepare operations orders manufacturer we're at believe to produced excited of We fully this installed for the communicated remain our timeline quarter, customers. packaging Defense this our phase third reduce as mentioned well being in the to last and and as have line we will completing moving, of testing. quarter our as cost the finally our expect initial as our previously operations XXXX. Department sales from increased contract commercial has currently batches we get as We're acceptance on of
to call Finally, have before and briefly believe securities these that I'd been like handing be are To over address filed. Raffi, vigorously to results. lawsuits through the call against lawsuits course. the over intend we take merit dismissed be the We without they to third clear, hand that believe due quarter to I'll the now you defend them. will financial to Raffi in
